| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 5mg |
|
||
| 10mg |
|
||
| 100mg | |||
| Other Sizes |
| Targets |
Rolziracetam's mechanism of action is not fully elucidated but is characteristic of the racetam family. It is thought to modulate neurotransmitter systems, such as glutamatergic or cholinergic pathways, which influence synaptic plasticity and cognitive function. Its primary target is not a single receptor but rather a neuromodulatory effect on the central nervous system.
|
|---|---|
| ln Vitro |
In vitro, rolziracetam is studied for its effects on neurotransmitter systems and synaptic plasticity. Its activity is assessed in neuronal cell cultures where it modulates glutamatergic or cholinergic pathways. These studies help to elucidate its mechanism of action as a nootropic agent. Its purity is >98% as confirmed by HPLC.
|
| ln Vivo |
In vivo, rolziracetam has been shown to improve short-term memory in rats and monkeys. This makes it a valuable compound for studying cognitive enhancement and the treatment of memory disorders. Its efficacy in animal models supports its classification as a nootropic drug.
|
| Enzyme Assay |
Cell-free assays for rolziracetam are not well-documented, as its mechanism is primarily studied in cellular and whole-animal models. Its molecular weight (139.15) and formula (C7H9NO2) are confirmed by mass spectrometry. Its purity (>98%) is confirmed by HPLC. Its physicochemical properties are typical of small molecule nootropics.
|
| Cell Assay |
Cellular assays for rolziracetam measure its effects on neurotransmitter release and synaptic signaling. These assays are conducted in neuronal cultures to study its modulation of glutamatergic or cholinergic pathways. Its effects on synaptic plasticity are also assessed. These studies provide insights into its mechanism of action as a cognitive enhancer.
|
| Animal Protocol |
In vivo animal experiments for rolziracetam are performed in rats and monkeys using memory tests such as short-term memory tasks. These studies measure improvements in cognitive performance after administration of the compound. The results demonstrate its efficacy as a nootropic drug and support its potential therapeutic applications.
|
| ADME/Pharmacokinetics |
Rolziracetam has a molecular weight of 139.15 and a molecular formula of C7H9NO2. It is a small molecule that is soluble in organic solvents. For storage, the powder can be kept at -20°C for 3 years, and in solvent at -80°C for 6 months or -20°C for 1 month. Its pharmacokinetic properties are characteristic of racetam-class compounds.
|
| Toxicity/Toxicokinetics |
The toxicological profile of rolziracetam is not extensively detailed. As a nootropic drug, it is generally considered safe at therapeutic doses. It has been studied in animal models without major reported toxicities. Its safety is inferred from its classification as a racetam, a class generally known for its favorable safety profile.
|
| References | |
| Additional Infomation |
Rolziracetam is a nootropic drug of the racetam family. It is also known as CI-911. It improves short-term memory in rats and monkeys. It acts as a neuromodulator in the central nervous system, influencing cognitive function and synaptic plasticity. It is a research compound and is not an approved drug for human use.
|
| Molecular Formula |
C7H9NO2
|
|---|---|
| Molecular Weight |
139.15
|
| Exact Mass |
139.063
|
| CAS # |
18356-28-0
|
| PubChem CID |
71893
|
| Appearance |
White to off-white solid powder
|
| Density |
1.28g/cm3
|
| Boiling Point |
274.9ºC at 760mmHg
|
| Flash Point |
130.5ºC
|
| Vapour Pressure |
0.00526mmHg at 25°C
|
| Index of Refraction |
1.548
|
| LogP |
0.235
|
| Hydrogen Bond Donor Count |
0
|
| Hydrogen Bond Acceptor Count |
2
|
| Rotatable Bond Count |
0
|
| Heavy Atom Count |
10
|
| Complexity |
180
|
| Defined Atom Stereocenter Count |
0
|
| InChi Key |
IEZDOKQWPWZVQF-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C7H9NO2/c9-6-3-1-5-2-4-7(10)8(5)6/h5H,1-4H2
|
| Chemical Name |
2,6,7,8-tetrahydro-1H-pyrrolizine-3,5-dione
|
| Synonyms |
CI 911; BRN 0121236; Rolziracetam
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~100 mg/mL (~718.65 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (17.97 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (17.97 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 2.5 mg/mL (17.97 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 7.1865 mL | 35.9324 mL | 71.8649 mL | |
| 5 mM | 1.4373 mL | 7.1865 mL | 14.3730 mL | |
| 10 mM | 0.7186 mL | 3.5932 mL | 7.1865 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
